Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 9, 2016. The filing serves to announce the company's financial and operational results for the quarter ended March 31, 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric; these figures are located in the referenced Exhibit 99.1.
Material Changes
The filing text does not disclose specific material changes or comparative data versus the prior period. It only confirms the issuance of a press release regarding the Q1 2016 results.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly references the attached press release for operational and financial details.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc. (the input metadata listed Altimmune, Inc., which is incorrect based on the filing text).
- Review Exhibit 99.1 (the Press Release dated May 9, 2016) to obtain actual revenue, cash burn, and operational milestone data.
- Confirm the reporting period is the quarter ended March 31, 2016.
- Note that the information in this 8-K is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference except as expressly stated.